Scarica l'app Stockscreener
26.00
1.70%
-0.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Immunovant Inc Borsa (IMVT) Ultime notizie
Immunovant (IMVT) Expected to Post Quarterly Earnings on Friday - MarketBeat
Breakout Zone: What are analysts price targets for Immunovant Inc2025 Volume Leaders & Weekly Top Stock Performers List - baoquankhu1.vn
Immunovant, Inc. (IMVT) Stock Analysis: Exploring a 51.55% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Investors Purchase High Volume of Call Options on Immunovant (NASDAQ:IMVT) - MarketBeat
Published on: 2026-01-26 14:49:08 - baoquankhu1.vn
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up - TipRanks
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence - MSN
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 - The Manila Times
Immunovant (NASDAQ:IMVT) CTO Jay Stout Sells 1,977 Shares - MarketBeat
(IMVT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Immunovant, Inc. (IMVT) Stock Analysis: A Biotech Marvel With 53% Potential Upside - DirectorsTalk Interviews
SG Americas Securities LLC Has $1.01 Million Stock Holdings in Immunovant, Inc. $IMVT - MarketBeat
Merger Talk: What are Immunovant Incs earnings expectationsTrade Risk Report & Precise Buy Zone Tips - baoquankhu1.vn
Assessing Immunovant (IMVT) Valuation After Strong 90 Day Share Price Momentum - Yahoo Finance
How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39% - Finviz
Immunovant (NASDAQ:IMVT) Stock Price Down 5.7%Should You Sell? - MarketBeat
Portfolio Update: Is Immunovant Inc stock gaining market share2025 Year in Review & Capital Efficient Trade Techniques - Bộ Nội Vụ
Truist lifts Immunovant (IMVT) PT to $22 on updated 2026 financial modeling - MSN
Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling - Insider Monkey
Sjogren’s Syndrome Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Astellas Pharma, Immunovant Sciences, NK Cells Artiva Biotherapeutics, Rise Therapeutics - Barchart.com
Price-Driven Insight from (IMVT) for Rule-Based Strategy - Stock Traders Daily
10 Promising Stocks to Buy Under $50 - Insider Monkey
Immunovant announces $550 million stock offering - MSN
Immunovant CTO Stout sells $32k in IMVT stock By Investing.com - Investing.com Australia
Immunovant CTO Stout sells $32k in IMVT stock - Investing.com
Immunovant (NASDAQ:IMVT) CTO Jay Stout Sells 1,203 Shares - MarketBeat
Immunovant (NASDAQ:IMVT) Reaches New 52-Week High on Analyst Upgrade - MarketBeat
Immunovant stock hits 52-week high at $27.71 By Investing.com - Investing.com India
Immunovant stock hits 52-week high at $27.71 - Investing.com
Market Recap: Can Immunovant Inc. stock maintain operating marginsWeekly Investment Summary & Real-Time Market Sentiment Alerts - Улправда
How Immunovant Inc. stock compares to industry benchmarksJuly 2025 Gainers & Smart Swing Trading Alerts - Улправда
How Immunovant Inc. stock performs in stagflationPortfolio Risk Report & Precise Trade Entry Recommendations - ulpravda.ru
What technical charts say about Immunovant Inc. stockWeekly Risk Summary & Free Fast Gain Swing Trade Alerts - ulpravda.ru
Immunovant (NASDAQ:IMVT) Price Target Raised to $22.00 at Truist Financial - MarketBeat
Wolfe Research upgrades Immunovant stock to Outperform on Graves’ disease potential By Investing.com - Investing.com South Africa
Wolfe Research Upgrades Immunovant (IMVT) - Nasdaq
Wolfe Research upgrades Immunovant stock to Outperform on Graves’ disease potential - Investing.com Nigeria
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire
Immunovant CEO Peter Salzmann sells $208,899 in stock - MSN
Wolfe Research Downgrades Immunovant (IMVT) - MSN
(IMVT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Immunovant (NASDAQ:IMVT) Nasdaq Today Immunology Innovation - Kalkine Media
Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
How Investors Are Reacting To Immunovant (IMVT) $550 Million Follow-On Equity Raise And Dilution - Sahm
Assenagon Asset Management S.A. Invests $3.31 Million in Immunovant, Inc. $IMVT - MarketBeat
Research Analysts Issue Forecasts for Immunovant Q3 Earnings - MarketBeat
1.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):